In this report, the Global Enteric Disease Testing Market has been segmented by Disease, Technology, Pathogen Tested, End Use and Geography.

Global Enteric Disease Testing Market, Segmentation by Disease

The Global Enteric Disease Testing Market has been segmented by Disease into Bacterial, Viral, and Parasitic.

Bacterial
Bacterial enteric diseases account for nearly 59% of the global enteric disease testing market. Pathogens such as Salmonella, E. coli, Shigella, and Campylobacter are common culprits behind foodborne outbreaks and traveler’s diarrhea. Due to their high incidence and potential for severe complications, bacterial testing is a priority in hospital labs, food safety programs, and epidemiological surveillance systems, driving demand for rapid culture, PCR, and multiplex platforms.

Viral
Viral enteric infections represent around 26% of the market, with norovirus and rotavirus being the most commonly detected. These viruses are highly contagious and often responsible for outbreaks in schools, cruise ships, and long-term care facilities. The availability of rapid antigen detection kits and real-time PCR assays has improved both diagnostic speed and outbreak management, particularly in pediatric and geriatric populations.

Parasitic
Parasitic enteric diseases, holding about 15% of market share, remain a concern in resource-limited settings. Organisms like Giardia, Cryptosporidium, and Entamoeba are prevalent in rural and underserved communities with inadequate water sanitation. As global health initiatives expand, there is increasing investment in cost-effective, sensitive diagnostics such as multiplex PCR, supporting better case management and public health responses.

Global Enteric Disease Testing Market, Segmentation by Technology

The Global Enteric Disease Testing Market has been segmented by Technology into Traditional and Rapid.

Traditional
Traditional enteric disease testing methods make up approximately 53% of the global market. These include culture-based diagnostics, microscopic stool examinations, and enzyme-linked immunoassays (ELISA), which are valued for their accuracy and cost-effectiveness. Despite being slower, they are still heavily relied upon in resource-limited settings and for confirmatory diagnosis in clinical laboratories. Their ability to identify live pathogens and support antibiotic susceptibility testing keeps them relevant in hospital-based diagnostics.

Rapid
Rapid diagnostic technologies account for nearly 47% of the market and are increasingly used in point-of-care and high-throughput settings. These include PCR-based assays, lateral flow devices, and automated multiplex panels, offering results within hours rather than days. With growing emphasis on early detection, outbreak control, and minimized hospital stays, rapid diagnostics are becoming the standard in developed healthcare systems and urgent care scenarios.

Global Enteric Disease Testing Market, Segmentation by Pathogen Tested

The Global Enteric Disease Testing Market has been segmented by Pathogen Tested into E. Coli, Salmonella, Campylobacter, Listeria, Other Pathogens.

E. Coli
E. Coli testing accounts for about 28% of the global enteric disease diagnostics market. Highly pathogenic strains like E. coli O157:H7 are linked to severe complications, including hemolytic uremic syndrome (HUS). Detection is commonly performed through rapid PCR assays, ELISA kits, and culture methods, especially in outbreak investigations and pediatric cases.

Salmonella
Salmonella diagnostics, comprising around 24% of the market, are central to foodborne disease surveillance and hospital-based diagnostics. With over 2,500 serotypes, it poses significant risk globally. Widely used tests include culture, serotyping, and real-time PCR, often employed in clinical microbiology labs and agricultural testing sites.

Campylobacter
Campylobacter testing makes up about 19% of the market. Despite its high incidence, it often goes untested due to special culture requirements. The rise of molecular diagnostics, particularly multiplex PCR, has improved detection rates in both public health programs and routine diagnostics.

Listeria
Listeria detection, representing approximately 11%, is critical for high-risk populations. This pathogen is frequently monitored in pregnant women and immunocompromised patients, as well as in ready-to-eat food products. Testing often involves enrichment steps followed by molecular confirmation to ensure accurate diagnosis and prevention of outbreaks.

Other Pathogens
The Other Pathogens segment (about 18%) includes tests for Shigella, Rotavirus, Norovirus, Giardia, and Cryptosporidium, among others. These pathogens are often included in syndromic panels and multiplex PCR assays, making diagnosis faster, more accurate, and cost-efficient—especially in outbreak-prone and pediatric care environments.

Global Enteric Disease Testing Market, Segmentation by End Use

The Global Enteric Disease Testing Market has been segmented by End Use into Food and Water,

Food
Food testing dominates the enteric disease testing market with a share of around 62%, driven by the need to detect microbial contamination in products such as meat, dairy, seafood, and packaged foods. Foodborne pathogens like E. coli, Salmonella, and Listeria pose significant risks to public health and brand reputation. As food export and import activity expands globally, companies are investing in rapid diagnostic technologies and automated detection systems to comply with international food safety standards.

Water
Water testing accounts for about 38% of the global market, serving as a frontline defense against waterborne outbreaks. Contaminants such as Shigella, Giardia, and cholera bacteria can quickly spread in communities with inadequate sanitation or compromised water infrastructure. Testing technologies are increasingly deployed in municipal water systems, humanitarian efforts, and remote fieldwork, where speed, portability, and affordability are critical. Governments and NGOs are scaling up efforts to ensure safe drinking water through frequent surveillance testing.

Global Enteric Disease Testing Market, Segmentation by Geography

In this report, the Global Enteric Disease Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Global Enteric Disease Testing Market Share (%), by Geographical Region, 2024

North America
North America dominates the global enteric disease testing market, contributing around 39% of total revenue. The region is characterized by stringent regulatory frameworks, advanced molecular diagnostic capabilities, and a strong focus on preventing foodborne and waterborne outbreaks. Agencies such as the CDC and FDA play a critical role in driving widespread testing adoption across clinical, environmental, and industrial sectors.

Europe
Europe holds an estimated 27% of the market, supported by harmonized EU food safety policies, well-funded epidemiological surveillance networks, and a culture of preventive healthcare. Growing demand for automated diagnostic platforms and multi-pathogen panels is expanding the market across healthcare and agri-food industries in the region.

Asia Pacific
Asia Pacific, with a share of about 22%, is the fastest-expanding regional market. High population density, urban migration, and poor water sanitation in several areas have made enteric diseases a major public health concern. As governments scale up efforts to improve diagnostic access and reduce diarrheal disease burden, testing demand is surging across both clinical and environmental settings.

Middle East & Africa
Middle East & Africa account for around 7% of global demand. While healthcare infrastructure varies, the increasing use of mobile testing labs, donor-funded screening programs, and international aid initiatives are helping improve diagnostics in underserved areas. The region is focusing on low-cost, scalable technologies for effective outbreak response.

Latin America
Latin America makes up nearly 5% of the market. Rising awareness of foodborne disease risks, combined with investment in laboratory capacity building, is gradually improving testing availability. Continued adoption of real-time PCR kits and multiplex detection technologies is expected as the region addresses public health gaps in water and food safety monitoring.